TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32745768
Drug: Coffee B
Normalized name: Coffee Bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee B (407 mg CGAs/day)
Study: 36308079
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 20 mg·kg‐1
Study: 33302802
Drug: 90 ml
Normalized name: 190 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 ml sea buckthorn puree for 90 days
Study: 33626904
Drug: Warfarin (later
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (later use at 1 week post-TIA or 2 weeks post-AIS)
Study: 33626904
Drug: Warfarin (later
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (later use)
Study: 32376110
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) hepatitis A vaccine
Study: 32376110
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) hepatitis A vaccine
Study: 33621009
Drug: Solifenacin 5mg
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin 5mg orally once daily
Study: 33621009
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pregabalin and solifenacin
Study: 32291094
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses thromboprophylaxis
Study: 36267027
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber supplementation (19.56 g day‐1)
Study: 33618051
Drug: Interval exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval exercise (IE) - 30 min at 100% peak work capacity (WRpeak) for 30s alternated with 40% WRpeak for 30s, 3 times weekly for 12 weeks
Study: 33618051
Drug: Constant-load exercise
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant-load exercise (CLE) - 30 min at 70% WRpeak, 3 times weekly for 12 weeks
Study: 34009282
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavior therapy (CBT) for 12 weeks (n = 51)
Study: 32386068
Drug: Noncultured epidermal
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncultured epidermal cell suspension (NCES)
Study: 34416295
Drug: Detoxifying and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detoxifying and blood-activating Chinese medicine granules (15 g of Polygonum cuspidatum and 10 g of Crataegus pinnatifida for 4 weeks)
Study: 34416295
Drug: Standardized Western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized Western medicine (control group)
Study: 32870471
Drug: Once-weekly semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly semaglutide 0.5 mg
Study: 36651820
Drug: Once-weekly semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly semaglutide 1.0 mg
Study: 33074557
Drug: Once-daily sitagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily sitagliptin 100 mg
Study: 33074557
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of semaglutide
Study: 33026160
Drug: Exenatide 2
Normalized name: exenatide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2 mg (ExQW)
Study: 35642157
Drug: Mirror Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror Therapy (MT) - corresponding movements of limbs, 15 min, 5 d/week for 2 weeks
Study: 32209798
Drug: Modified lower-calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified lower-calorie diet (MD) for 12 weeks, reducing daily energy intake by 30%
Study: 32496449
Drug: Atropine 0.004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.004 mg/kg intravenously
Study: 35086737
Drug: pharmacogenomic-driven chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pharmacogenomic-driven chemotherapy
Study: 35086737
Drug: standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard adjuvant chemotherapy
Study: 32536013
Drug: Abemaciclib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib (150 mg twice daily) plus nonsteroidal aromatase inhibitor (NSAI)
Study: 32536013
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus nonsteroidal aromatase inhibitor (NSAI)
Study: 32272959
Drug: 12.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 μg misoprostol sublingually
Study: 32272959
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg misoprostol vaginally
Study: 35086385
Drug: Orbital atherectomy
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital atherectomy (OA) with adjunctive drug-coated balloon (DCB) angioplasty
Study: 34837899
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) intervention, 6 sessions every 2 days
Study: 32920647
Drug: BUP‐XR (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP‐XR (extended-release subcutaneous buprenorphine)
Study: 35853489
Drug: Monthly injection
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly injection of pegcetacoplan (AM)
Study: 35853489
Drug: Injection every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection every other month of pegcetacoplan (AEOM)
Study: 36367998
Drug: Enzalutamide (ENZA)
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide (ENZA) 160 mg once daily for 6 months
Study: 34666767
Drug: JTA-200/2 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTA-200/2 (200 μg clonidine and 20 mg hyaluronic acid in 2 ml)
Study: 34666767
Drug: JTA-004 (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTA-004 (pooled data from all formulations)
Study: 34666767
Drug: Reference treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatment (hylan G-F 20)
Study: 35794728
Drug: Coloring therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coloring therapy combined with conventional therapy
Study: 35794728
Drug: Conventional antianxiety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antianxiety medication and physical therapy
Study: 32362479
Drug: Flurbiprofen patch
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen patch (FPP)
Study: 32362479
Drug: S-Flurbiprofen patch
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-Flurbiprofen patch (SFPP)
Study: 32362479
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no patch)
Study: 36323482
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care approach including app-intervention, two telephone counselling sessions (50 min each), and online therapy over 17 weeks (15 weekly group sessions, 8 individual sessions).
Study: 37901346
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 and 300 mg every 2 weeks
Study: 35988464
Drug: Intrapartum azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrapartum azithromycin (2g oral)
Study: 34823296
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (281 patients)
Study: 34823296
Drug: Sequential chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemoradiotherapy (285 patients)
Study: 34713987
Drug: PB2452 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB2452 6 g i.v. bolus followed by 6 g infused over 4 h and then 6 g over 12 h
Study: 33857436
Drug: ENDS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENDS with 36 mg/mL nicotine
Study: 33857436
Drug: ENDS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENDS with 0 mg/mL nicotine
Study: 33857436
Drug: ENDS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENDS with 8 mg/mL nicotine
Study: 36268807
Drug: Neurotec® herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotec® herbal capsule (100 mg twice a day for three months)
Study: 34837931
Drug: Mucosamin spray
Normalized name: chondroitin sulfates / glucosamine Oral Tablet [Cosamin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosamin spray (3-4 times a day)
Study: 34837931
Drug: Standard medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medications (3 times a day)
Study: 35134800
Drug: Tablet of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet of innovator product (FSt)
Study: 33546734
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of RAAS inhibitors
Study: 33546734
Drug: Temporary discontinuation
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary discontinuation of RAAS inhibitors
Study: 34580114
Drug: Veliparib plus
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib plus modified FOLFIRI (veliparib 200 mg twice daily, days 1-7 with mFOLFIRI days 3-5)
Study: 37669281
Drug: Supported Protocolized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supported Protocolized Discontinuation (SPD) alone
Study: 35450055
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (3 mg/kg/day for 5 days)
Study: 35450055
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline infusion (50 ml/day for 5 days)
Study: 32536425
Drug: TPVB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPVB with 20 mL 0.25% bupivacaine
Study: 36342252
Drug: 532-nm picosecond
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 532-nm picosecond laser treatment (3 monthly treatments, 800 ps pulse duration, 4-6mm spot size, 0.1 to 0.6J/cm2 fluence)
Study: 36342252
Drug: 532-nm picosecond
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 532-nm picosecond laser treatment
Study: 33756525
Drug: High-quality multi-ingredient
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quality multi-ingredient nutritional supplement (SUPP) - 20 g whey protein, 2 g leucine, 2.5 g creatine monohydrate, 300 mg calcium citrate, 1000 IU vitamin D, ingested twice daily
Study: 33756525
Drug: Isontrogenous isoenergetic
Normalized name: Octisalate 0.05 g in 1 mL / Avobenzone 0.03 g in 1 mL / Octinoxate 0.029 g in 1 mL / Octocrylene 0.022 g in 1 mL TOPICAL LOTION [For Men Maca Root Energetic Face Protector SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isontrogenous isoenergetic placebo (PL) - 20 g collagen peptides, 1.4 g alanine, 0.6 g glycine, ingested twice daily
Study: 33756525
Drug: High-quality multi-ingredient
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quality multi-ingredient nutritional supplement (SUPP)
Study: 34611051
Drug: Astaxanthin 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin 6 mg/day for 4 weeks
Study: 33819166
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy with bilevel positive airway pressure (BiPAP) ventilation
Study: 33819166
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative respiratory and physical therapy techniques
Study: 32021143
Drug: Glycopyrrolate/formoterol fumarate
Normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 µg
Study: 32949031
Drug: Ceftolozane/tazobactam (C/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane/tazobactam (C/T) 3-g dose (2 g ceftolozane and 1 g tazobactam) administered via a 1-hour infusion every 8 hours
Study: 33653009
Drug: High-NO3- (HN:
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-NO3- (HN: 2 × 70 mL BJ/day)
Study: 33653009
Drug: Medium-NO3- (MN:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-NO3- (MN: 70 mL BJ/day)
Study: 33653009
Drug: Low-NO3- (LN:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-NO3- (LN: 70 mL BJ on alternate days)
Study: 33653009
Drug: Placebo (PL:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL: 70 mL of NO3--depleted BJ on alternate days)
Study: 35907163
Drug: Indoor daylight
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoor daylight photodynamic therapy (idl‐PDT)
Study: 32229771
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training with protein supplement (21 g whey protein per day, 90 kcal)
Study: 38140854
Drug: Intravenous belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous belimumab 10 mg/kg
Study: 34560137
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with standard therapy (cyclophosphamide/azathioprine or mycophenolate mofetil)
Study: 34069621
Drug: Group multicomponent
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group multicomponent cognitive‐behavioral therapy
Study: 33983051
Drug: Zelesse cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zelesse cream (monotherapy for non-infectious VV)
Study: 33983051
Drug: Zelesse cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zelesse cream (adjuvant to antimicrobial therapy for infectious VV)
Study: 35784687
Drug: Withania somnifera
Normalized name: WITHANIA SOMNIFERA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withania somnifera (WS) root capsules, given twice a day for 12 weeks
Study: 35784687
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch capsules), given twice a day for 12 weeks
Study: 35126900
Drug: Early enteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early enteral nutrition (EEN) support combined with chemotherapy
Study: 33031833
Drug: Bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (400 mg once daily for 21 days)
Study: 34046892
Drug: Topical Epigallocatechin-3-gallate
Normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Epigallocatechin-3-gallate (EGCG)
Study: 34523740
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol treatment (800 ?g single dose)
Study: 38200581
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg daily)
Study: 32349927
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) plus docetaxel and estramustine (DE)
Study: 39475860
Drug: Multi-Ingredient Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-Ingredient Supplement (MIS)
Study: 33880554
Drug: Specialized nutritious
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized nutritious food (SNF) treatment (1 of 4 types: 3 fortified-blended foods or a lipid-based nutrient supplement)
Study: 35584475
Drug: Wheelchair basketball
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheelchair basketball (2 hours, twice a week for 12 months)
Study: 34228837
Drug: Candesartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan treatment in the DIRECT-Protect trials
Study: 34048061
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (660 nm 200 mW CW applied at a distance of 1 cm to 4 points on the occlusal area, and 810 nm 200 mW CW applied at tissue surface at three points on the buccal and three points on the lingual gingiva for 15 seconds)
Study: 33514571
Drug: Leucine-rich protein
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine-rich protein supplement
Study: 34844061
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted manual-assisted problem-solving training (C-MAP) plus treatment as usual (TAU)
Study: 39012102
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered to 4 patients)
Study: 32977969
Drug: Cardioplegia with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioplegia with diazoxide (500 μmol/L)
Study: 36125279
Drug: Ubrogepant 25
Normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ubrogepant 25 mg
Study: 32073660
Drug: Ubrogepant 50
Normalized name: ubrogepant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubrogepant 50 mg (pooled)
Study: 35569466
Drug: PBRT alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBRT alone (64.8–70.2 Gy at 1.8 Gy per fraction daily)
Study: 34173988
Drug: Photobiomodulation (PBM.G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM.G)
Study: 34173988
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C.G)
Study: 35701067
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tadalafil (one time per day) and placebo (one time per day)
Study: 35701067
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tadalafil (two times per day)
Study: 34636057
Drug: Topical glycopyrronium
Normalized name: glycopyrronium Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glycopyrronium tosylate 3.75%
Study: 34636057
Drug: Topical glycopyrronium
Normalized name: glycopyrronium Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glycopyrronium tosylate 2.5%
Study: 35034478
Drug: Glucocorticoid, immunosuppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid, immunosuppressant and other drugs (Control Group)
Study: 36507329
Drug: H2 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 inhalation therapy
Study: 36507329
Drug: Control (air
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (air inhalation)
Study: 36350049
Drug: Tobacco treatment
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco treatment intervention offered during lung cancer screening at multiple clinical timepoints (RP1, RP2, RP3)
Study: 32719050
Drug: Online evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online evidence-based medicine (EBM) supplement
Study: 34428646
Drug: Hydroxy selenomethionine
Normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxy selenomethionine (OH‐SeMet) supplementation at 0.2, 0.4, 0.6, and 0.8 mg/kg
Study: 34428646
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 0.0 mg/kg Se
Study: 32201122
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (steroid)
Study: 32201122
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer solution (placebo)
Study: 34835970
Drug: Zinc deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc deficiency defined as serum Zn concentration <9.9 µmol/L
Study: 616082294
Drug: New high
Approvals — FDA: no, EMA: no, PMDA: no
Description: New high viscosity formula (OGD, Refresh Optive Gel Drops, Allergan)
Study: 616082294
Drug: Systane Gel
Normalized name: PEG-400/Propylene Glycol 0.4%-0.3% Ophthalmic Solution [SYSTANE GEL DROPS]
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systane Gel Drops (SGD, Alcon)
Study: 616082294
Drug: Genteal Lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genteal Lubricant Gel Drops (GGD, Novartis)
Study: 34330043
Drug: 3-lesson unguided
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-lesson unguided online treatment program targeting rumination and worry
Study: 34108036
Drug: Medication monitor
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication monitor reminders and differentiated care (Wisepill evriMED 1000)
Study: 34108036
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (medication monitors for adherence tracking, TB education, normal clinic follow-up)
Study: 33252635
Drug: Erbium-YAG laser
Normalized name: erbium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erbium-YAG laser treatment
Study: 33833857
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality (VR) treatment
Study: 35241087
Drug: SHR3680 (80mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR3680 (80mg, 160mg, 240mg daily)
Study: 35241087
Drug: SHR3680 (40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR3680 (40mg to 480mg daily)
Study: 32716589
Drug: Delayed-loaded implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-loaded implants
Study: 33960504
Drug: Oral paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral paclitaxel 615 mg/m2 with encequidar 15 mg
Study: 33960504
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel 80 mg/m2
Study: 34957952
Drug: 5 drops
Normalized name: Bifidobacterium animalis 1 billion cell/5 drops ORAL DROPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 drops of oral synbiotic daily along with phototherapy
Study: 34787778
Drug: Afatinib 30
Normalized name: afatinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 30 mg with daily TMZ and RT
Study: 34787778
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg with RT alone